Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®

Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal investigator, and Dr. Alain Herrera, a seasoned industry executive, has joined Isofol as advisors to its Board of Directors.

Isofol Medical AB (publ), a clinical stage oncology company, announces that a cooperation has been established with Professor Sten Nilsson and Doctor Alain Herrera who have joined Isofol as advisors to its Board of Directors. In addition to several of the World’s leading oncologists being part of Isofol’s Advisory Board this strengthens the company with additional expertise within pharmaceutical business strategy, clinical development, and management of the registration process in preparations for the upcoming pivotal study ISO-CC-007, where Modufolin®, with the support of both FDA in the USA and EMA in Europe, is evaluated as a first-line treatment for metastatic colorectal cancer in an effort to provide data for directly taking Modufolin® to potential drug marketing approval.

Professor Sten Nilsson

Dr. Nilsson, MD, PhD, is one of Scandinavia’s leading clinicians in urological oncology. He has served as a Professor of Oncology at the Karolinska Hospital, Stockholm, Sweden and has wide ranging clinical and research experience in the fields of oncology and nuclear medicine. In the industry, Prof. Nilsson has been part of the advisory boards of several leading pharmaceutical companies such as Bayer Healthcare, Janssen, Ipsen, Novartis, AstraZeneca, Pharmacia/Pfizer, Roche and Lilly. He is founder of Dextech Medical (Aktietorget, Stockholm) and is providing scientific and strategic advice as a member of the board of PledPharma (Nasdaq First North), and Spago Nanomedical (Aktietorget, Stockholm).

Doctor Alain Herrera

Dr. Alain Herrera, MD, PhD has contributed directly to the worldwide registration of, among others, the cytostatic oxaliplatin. Oxaliplatin in combination with fluorouracil and leucovorin constitute one of today’s basic regimens, FOLFOX, in treatment of colorectal cancer. Currently Dr. Herrera operates as a Senior Consultant within the field of Oncology. Prior to this Dr. Herrera held the position of Vice President of Global Oncology Business Strategy and Development at Sanofi and before that he was Head of Global Oncology Franchise at Sanofi. Dr. Herrera has also served as Chairman of Chiron Therapeutics Europe and as Managing Director of Pierre Fabre Oncology Laboratories. Dr. Herrera is part of the Supervisory Board of, among others; IDDI, Nanobiotix, PDCline Pharma, Gustave Roussy-Transfert and Arcad Foundation.

For more information, please contact:

Anders Rabbe, CEO, Isofol Medical AB


Phone: +46 (0)707 646 500

About Modufolin®

Modufolin® (active ingredient [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert its effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin® is currently being evaluated in a clinical Phase II study.

About Isofol Medical AB

Isofol Medical AB is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin® with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the NASDAQ First North Premier. Certified Adviser is FNCA Sweden AB.

Scroll to Top